BioNTech's Lung Cancer Drug Just Doubled What Chemo Could Do
BioNTech's experimental drug gotistobart nearly doubled overall survival compared to chemotherapy in one of lung cancer's toughest-to-treat subtypes. The result could reshape second-line treatment for squamous NSCLC and rewrite BioNTech's identity as an oncology company.
The Number That Turned Heads
Imagine your doctor tells you a treatment could give you 10 months. Now imagine someone walks in and says they can give you 18.5. That's not a rounding error. That's nearly double.
That's exactly what BioNTech just showed at the IASLC 2026 World Conference on Lung Cancer on September 14. Its experimental drug gotistobart delivered median overall survival of 18.5 months in patients with previously treated squamous non-small cell lung cancer (a particularly stubborn form of lung cancer that starts in the flat cells lining the airways). The comparator, docetaxel, a chemotherapy drug that's been the go-to second-line option for years? 10.0 months.
In a disease where second-line treatments have barely moved the needle in decades, this is the kind of result that makes oncologists lean forward in their chairs.
Why Squamous Lung Cancer Is Such a Beast
Lung cancer is the world's deadliest cancer. Squamous NSCLC is one of its most frustrating subtypes. Patients typically receive immunotherapy plus chemotherapy as their first treatment. When that stops working (and it usually does), the options get bleak fast.
The standard fallback is docetaxel, a chemo drug that's been around since the '90s. It doesn't work great. Real-world studies peg second-line overall survival at roughly 7.7 months across advanced NSCLC patients, with low response rates that make oncologists wince. There's no targeted therapy magic bullet here, either; squamous tumors rarely carry the genetic mutations (like EGFR or ALK) that let other lung cancer patients access precision medicines.
So if you're a squamous NSCLC patient whose first treatment failed, you're essentially stuck with a drug that buys you a handful of months. That's the backdrop against which BioNTech just dropped its data.
A Smarter Way to Unleash the Immune System
Gotistobart (also known as BNT316 or ONC-392) isn't your typical cancer drug. It targets a protein called CTLA-4, the same target that ipilimumab (Yervoy) made famous over a decade ago. But there's a twist that makes it fundamentally different.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Think of CTLA-4 as the brakes on your immune system. Blocking it can supercharge your body's ability to fight cancer. The problem? First-generation CTLA-4 drugs were like ripping the brake lines out entirely: powerful, but the side effects could be brutal. Your immune system would attack healthy tissue alongside the tumor.
Gotistobart takes a more surgical approach. It's designed with pH-sensitive binding, meaning it grabs onto CTLA-4 at normal body pH but dissociates from CTLA-4 inside acidic endosomes and lysosomes within cells, allowing CTLA-4 to recycle back to the cell surface in normal tissues. The practical result: it depletes the regulatory T cells (the immune cells that protect tumors from attack) inside the tumor itself, while leaving the rest of your immune system's checks and balances more intact.
It's like having a bouncer who only causes trouble at the right bar.
Inside the PRESERVE-003 Trial
The data came from stage 1 of the PRESERVE-003 trial, a global, randomized, open-label Phase 3 study. Patients had metastatic squamous NSCLC without targetable genetic mutations, and their cancer had progressed despite prior immunotherapy and platinum-based chemotherapy. In other words, these were patients who had already failed the best available treatments.
The trial tested gotistobart (6 mg/kg every three weeks, with two higher loading doses of 10 mg/kg) against docetaxel at its standard dose. The primary endpoint was straightforward: overall survival. Did patients live longer?
The hazard ratio came in at 0.56, with a nominal p-value of 0.0295. For non-statisticians, that hazard ratio means gotistobart cut the risk of death by 44% compared to chemo. The p-value suggests this wasn't a fluke, though the "nominal" label means the result still needs confirmation in the larger pivotal stage of the trial, which plans to enroll roughly 500 additional patients with squamous histology only.
What Wall Street Is Saying
Analysts at BMO said the findings "further confirm" gotistobart's survival advantage and highlight the "potential for non-chemotherapy-based treatment in sqNSCLC." That's a measured statement, but read between the lines: a chemo-free option that nearly doubles survival in this population would be a genuine paradigm shift.
BioNTech hasn't been on many oncologists' shortlists as a serious immuno-oncology player. The company is still best known for its COVID-19 mRNA vaccine with Pfizer. But that reputation is shifting. BioNTech now has 15 Phase 3 trials running and expects seven late-stage readouts in 2026 alone, spanning next-generation immunomodulators, antibody-drug conjugates, and mRNA cancer therapies. The company has assembled a web of partnerships with the likes of BMS, Genentech, and Genmab to accelerate its oncology ambitions.
Gotistobart, developed in collaboration with OncoC4, is arguably the crown jewel of that effort right now. It already holds FDA Fast Track Designation for NSCLC patients progressing after anti-PD-(L)1 therapy, plus Orphan Drug Designation specifically for squamous NSCLC.
The Bigger Picture: Portfolio Play, Not a One-Hit Wonder
BioNTech isn't betting on gotistobart as a standalone product. The company's strategy is to build a portfolio-based immuno-oncology platform where gotistobart can serve as a backbone for combination regimens across lung cancer and other solid tumors. Additional trials are exploring the drug in metastatic castration-resistant prostate cancer, platinum-resistant ovarian cancer, and other tough indications.
This matters because the immuno-oncology landscape is fiercely competitive. AstraZeneca, Bristol-Myers Squibb, Merck, and Roche all have deep IO franchises. A single positive readout won't dethrone any of them. But a drug that can slot into multiple combinations across multiple tumor types? That's a different conversation entirely.
What Comes Next
The stage 2 pivotal portion of PRESERVE-003 will randomize patients 1:1 to gotistobart versus docetaxel, focusing exclusively on squamous NSCLC. Overall survival remains the primary endpoint, with progression-free survival, response rate, and duration of response as secondary measures. If the pivotal data confirm what stage 1 just showed, BioNTech will have a strong case for regulatory approval.
For now, the signal is striking: in a patient population that has been largely abandoned by innovation, gotistobart just showed it could nearly double survival compared to the decades-old standard. The vaccine company from Mainz, Germany, might just be turning into a cancer company, too.
Deals & M&A5 min read
Novo Nordisk Just Walked Away from a $285M Obesity Bet. Why?
Novo Nordisk just killed a $285 million partnership with Ascendis Pharma to develop a once-monthly GLP-1 obesity shot. In the middle of the biggest obesity drug race in history, why would you hand back that asset? The answer says a lot about where the market is heading.
